Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China Prof Shun Lu, MDa,† Send email to shunlu@sjtu.edu.cn ∙ Prof Baogang Liu, MDb,† ∙ Prof Yongzhong Luo, MDc,† ∙ Prof Longhua Sun, MDd,† ∙ Prof Lin Wu, MDc,† ∙ Prof Zhengxiang Han, MDe ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00966-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_asco26&_hsenc=p2ANqtz-9g8nFSiWYmWS6GIcdQy-ne0gMn_25Nu_7PlYMtrZu6DiaBjpMr0LL1qgQIdA_Sxs8Z354DNyG5NEYSCzwm0mgPWYAkEA&_hsmi=421795296&utm_content=421795296&utm_source=hs_email